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Abstract
Medications administered by anesthesia health care providers and subsequently excreted
into the water supply system have the potential to affect ecological systems. Presently, there is a
lack of literature examining which medications or metabolites enter the waste stream. Further,
assessments of their potential environmental impact are often unknown or simply not considered
as an externality of medical practice. Recent work examining the practice of anesthesiology has
explored the solid waste stream, and the global warming potential of anesthetic gases, however
the potential aquatic impacts remain unexplored. To address the potential for waterborne
pollution and environmental toxicity, we extracted the total intravenous medications (by mass)
administered by anesthesiologists in 2017 at The University of Vermont Medical Center
(UVMMC), a mid-size regional Level 1 trauma center in Burlington, VT. The most commonly
administered medications were: cefazolin, propofol, acetaminophen, sugammadex and lidocaine.
To estimate the amount of each medication that entered the wastewater stream, we used
published metabolism profiles to adjust from the total amount administered to the amount
excreted unchanged or as prominent metabolites. For each medication we reviewed existing
literature concerning their environmental fate and impacts in water. Due to the constraints of
current knowledge, it is not possible to determine the exact fate and impacts of these drugs.
Some medications, like propofol, have the potential for significant bioaccumulation and
persistence. Others, such as lidocaine and acetaminophen, have short half-lives in the
environment but their constant delivery and excretion result in pseudo-persistence. The current
literature mostly assesses acute exposure at doses higher than could be expected in the
environment on select species. While significant toxicities across a variety of species have been
found repeatedly, chronic low dose exposures require further study for all the medications
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discussed. Finally, multi-drug impacts are likely to be more impactful than single-drug
toxicities. While we cannot state definitive impacts, the pharmaceuticals most used in
anesthesiology have a clear toxic potential and future studies should more closely examine the
relative contribution of anesthesia to pharmaceutical pollution, as well as points of intervention
for minimizing these unintended consequences of healthcare delivery.
Introduction
As large-scale industrial facilities that operate 24/7 every day of the year with a mandate
of supporting human health, hospitals have an opportunity and responsibility to promote
practices that minimize environmental damage [1,2]. Healthcare facilities have been estimated to
produce almost 10% of total greenhouse gases in the U.S. [3], and at over 4 billion tons of waste
each year, the healthcare industry as a whole produces is the second largest source of waste in
the U.S. [4]. Many calls to action have been placed to reduce the unintended environmental and
public health consequences of medical care [5-7], and efforts by several national and
international organizations—including Health Care Without Harm, Practice Greenhealth, the
Green Guide for Healthcare, and the Healthier Hospitals Initiative—are already underway to
reduce healthcare’s ecological footprint. Surgery and the entire perioperative process are areas
that appear to remain major drivers of resource use and pollution in healthcare.
Within healthcare, surgical departments and operating rooms (OR) are extremely costly,
accounting for about 40% of hospital costs. Although perioperative processes account for 40% of
costs, they may actually be responsible for 70% of hospital wastes [8]. Previous research on the
environmental consequences of medical care suggest that high costs of care correspond, in part,
to a heavy reliance on medical supplies, including single-use materials which each have
potentially large ecological footprints that accumulate throughout the supply chain from resource
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extraction, manufacturing, processing, packaging, transport, and disposal [5,9]. ORs use a wide
variety of resources from water and plastics to anesthesia gases, all of which have different
environmental impacts. Further, lifecycle considerations given the choice between disposable
and washable equipment carries its own complexity. Previous studies have found that a single
procedure could create more waste than that produced over a week by a family of 4 [10]. A
single surgeon scrubbing in for a procedure can use 50 liters of water [11].
OR management could become more sustainable should hospital systems focus on and
mitigate any potential waste streams. For example, previous work analyzing hand surgery found
that eliminating just a handful of extraneous items from disposable packs used in those
procedures accounted for over $40,000 in annual savings [12]. Also, a larger commercial effort
to recycle OR equipment saved over 2000 tons of landfill waste and nearly $140 million in 2008
alone [12]. Presumably, the reduction of materials consumed in the OR has a three-fold benefit:
it saves the hospital money and thus reduces the cost of procedures; decreased procedural costs
lower health care expenses, possibly stemming the ballooning cost of health in the U.S.; and
finally, it mitigates the environmental externalities inherent to the provision of perioperative
care.
While previous work has analyzed the impacts of anesthesia gases and solid waste
resulting from ORs [13-16], there is a dearth of literature regarding the intravenous medications
used and their impact on surface waters. Medications, given in high quantities during the
perioperative process, are metabolized and excreted into hospital and municipal waste water
systems. Although hospital wastewater is typically treated via municipal wastewater treatment
facilities, these facilities are not designed to remove the myriad of chemicals and agents that are
administered in healthcare [17] and are known sources of pharmaceuticals in the environment
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[18-20]. In national reconnaissance studies, pharmaceuticals have been detected in 80% of
surface waters tested in the U.S. [21] and 100% of 25 large municipal drinking water systems
[22].
While the relative contribution of various sources is unknown, hospital wastewater plays
a role in the pharmaceutical pollution of surface waters. In order to examine the potential
environmental impacts of those medications on its receiving waters of Lake Champlain (which
lies between Vermont and New York), we extracted the total intravenous medications (by mass)
administered by anesthesiologists in 2017 at The University of Vermont Medical Center
(UVMMC), a mid-size regional Level 1 trauma center in Burlington, VT. All medications are
tracked on PICIS (Picis Clinical Solutions, Inc., Wakefield, MA). Wastewater from the
UVMMC is treated by the Burlington Department of Public Works prior to being released into
Lake Champlain. Of note, Lake Champlain is the primary source for Burlington’s public
drinking water supply.
Discussion
In 2017, anesthesia health care providers administered over 35 kilograms of medications
with varied potentials for concern at the University of Vermont Medical Center, the five most
common medications were Cefazolin, Acetaminophen, Sugammadex, Lidocaine and Propofol
(Table 1). The Burlington’s wastewater treatment plants process all of the hospital effluent.
These plants use conventional activated sludge technologies and are occasionally unable to
process all wastewater resulting in untreated water entering Lake Champlain without treatment
[23,24].
Cefazolin
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Cefazolin, an antibiotic administered for surgical prophylaxis, represents the largest drug
by mass administered during the perioperative process at UVMMC in 2017. Cefazolin was given
13,003 times for a total of 23.81 kg, 20 kg more than the next highest mass drug. Not only is
cefazolin administered frequently, but it is also one of the most wasted and discarded antibiotics
[25]. This suggests that the total amount of cefazolin that enters the waste-stream from the
practice of anesthesia could be significantly greater than the total administered to patients due to
cefazolin that is discarded rather than administered to patients. Cefazolin does not undergo
significant metabolism and is excreted by the kidneys unchanged [26]. Thus, potentially all of
the 23.81 kg found their way into the wastewater systems. Cefazolin has been found in general
hospital water effluent at concentrations around 6.2 mg/L and may be reaching the environment
in significant quantities [27].
Despite its relatively long history, the environmental effects of cefazolin have not been
thoroughly studied [28]. Cefazolin has been shown not to harm green microalgae (Selenastrum
capriconutum and Chlorella vulgaris) – cornerstones of the aquatic ecosystems [29]. On the
other hand, in the aquatic environment, cefazolin is susceptible to photo-transformation and
chlorination into toxic byproducts [30]. Further, cefazolin is known to be highly teratogenic in
zebra fish at 100 µg/mL (as compared to the 6.2 µg/mL found in hospital effluent) and thus, may
have significant impacts on aquatic environments [31,30].
Current conventional wastewater treatment does not fully remove cefazolin and other
cephalosporins. Cefazolin has been measured entering wastewater plants from 0.08 to 8.79
µg/mL and leaving those plants at levels as high as 3.8 µg/mL [32]. While these measurements
came from Hong Kong which is clearly quite different from Burlington, Vermont they highlight
the incomplete removal of cefazolin by wastewater treatment plants. Two wastewater treatment
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methods - photolysis and adsorption – can remove cefazolin; however, results are inconsistent
and further technologies may be required for full removal from wastewaters [30]. Although
photolysis is a technology designed to remove chemicals, its use may be unwise in the context of
cefazolin removal given the potential for toxic by-products. Despite unclear aquaticenvironmental concerns, the growing numbers of antibiotic-resistant bacteria in wastewater
treatment plants should prove alarming [30].
Propofol
Propofol was the second most administered drug by mass at 3.70 kg distributed in 48,500
doses. The amount of propofol in the hospital waste-stream is likely substantially larger as it is
one of the most wasted medications whereby 1/3 to ½ of the drug is usually discarded rather than
administered to patients [25,33]. As one of the cornerstone drugs of anesthesia, understanding its
potential impact is crucial. Less than 1% of propofol is excreted unchanged while about 60%
undergoes hepatic glucuronidation and the remainder is oxidized into several different quinol
products [34],[35]. Therefore, a maximum of 37 g of unchanged propofol could have ended up
into the water system.
Although propofol levels in French hospital wastewater streams approach 17.5 µg/L, it
appears that the drug does reach wastewater treatment plants [36]. However, other studies show
higher levels of propofol leaving wastewater treatment plants than in the incoming waters,
potentially due to de-glucuronidation [37]. Approximately 60 times more propofol is excreted in
the glucuronidated form than the native formulation. Therefore, it is possible that any measured
levels are drastically underestimating the potential amount in waters. Given the significant
amount of glucuronidated propofol, the contribution from anesthesia services at the UVMMC
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may have up to an additional 2.22 kg from de-glucuronidation in addition to the original 37 g of
pure propofol.
While the current evidence on propofol reaching the environment is sparse, there are
significant concerns regarding its potential environmental impact. Propofol may bioaccumulate
in organisms due to its fat solubility, although studies show lower than theoretically expected
results [38]. Ecotoxicity testing has found impacts on a large range of species from growth
inhibition and death of algae, to acute toxicity in small crustaceans (Daphnia magna), and
freshwater fish (blue gill sunfish and rainbow trout) [38]. There are limited data regarding
chronic exposure, although laboratory studies show it impacts the survival, growth and
reproduction of Daphnia magna [38]. Understanding long-term exposure is of particular
importance because propofol is not readily degraded [38]. Conventional wastewater treatment
methods, including aerobic removal by activated sludge or anaerobic digesters are minimally
effective [38].
Once in the aquatic environment, propofol is not significantly photolyzed in water [38].
In fact, propofol must be incinerated at >1000°C for over 2 seconds – an impractical target to
reach via any standard public water treatment method – to fully remove the drug
[25].Additionally, propofol is highly mobile in soils and therefore, may accumulate significantly
both on land if deposited via biosolid waste, as well as in water near wastewater release points
[38].Aquatic accumulation is particularly likely given the estimated aquatic half-life of greater
than 1 year [38]. In sum, propofol has the potential for bioaccumulation, has both acute and
chronic aquatic toxicity, and does not readily degrade [25,38]. The current manufacturer
assessment states that the overall environmental risk is predicted to be low based on less than 1%
of propofol being excreted unchanged [38]. Again, the potential for significant amounts of the
10

~60% of excreted glucuronidated propofol to become propofol in the environment suggests that
the current impact could be 60 times greater than currently estimated.
Acetaminophen
In 2017, the anesthesia health care service administered a total of 3.35 kg of
acetaminophen over 4478 doses. Acetaminophen is mostly metabolized by kidneys with only 5%
excreted unchanged. Therefore, we estimated that 170 grams of pure acetaminophen (equivalent
to 523 standard over the counter pills) were excreted into the water as a result of the practice of
anesthesia at UVMMC. Drug metabolism is distributed an average as 55% apap-glucose, which
is divided between renal and biliary excretion; 37% as apap-sulfate excreted through the kidneys,
and 7% becoming n-acetyl-p-benzoquinone-imine (NAPQI). NAPQI then undergoes a set of
reactions concluding with apap-mercapturic acid [39].
Although the perioperative arena only accounts for a small portion of acetaminophen
delivered in a hospital system, acetaminophen is one of the most prescribed drugs across the
world and is available over the counter in many countries - further necessitating an
understanding of its environmental impacts as well as the large amount taken as an over-thecounter medication. Acetaminophen has been found in waters across the US, Europe and the
world in concentration as high as 65 µg/L in Great Britain [40]. In the US, it has been detected in
24% of stream water samples [41] and it has even been found to survive into drinking waters
[42].
Due to its frequency, persistence and toxic potential, acetaminophen has been labeled a
priority drug for water cycle assessments and is generally considered to have significant
ecological hazard potential [41,43,44]. While it is well-established that acetaminophen causes
hepatotoxicity in humans and mammals at high doses, the aquatic impacts are not as well studied
11

[43]. Acetaminophen has been found to be acutely toxic to nearly all species, including bacteria,
algae and macrophytes and crustaceans, in a standard battery of aquatic environmental tests
organisms including bacteria, microalgae, aquatic plants, and crustaceans [40].Acetaminophen
has been found to be specifically neurotoxic to freshwater shrimp and planarians [40]. Of note,
the toxicity was elicited at lower doses in the crustaceans than the microorganisms. While these
results were seen at doses orders of magnitude greater than currently documented in wastewaters,
the potential for non-fatal or non-growth arresting chronic impacts at lower doses is significant
and has been demonstrated at doses in the µg/L range in marine and freshwater clams [43,40].
Studies of these bivalves are particularly important as they are crucial elements in ecosystems
and are also filter feeders and thus accumulate higher levels of environmental pollutants [43].
Finally, acetaminophen disrupts the endocrine systems and inhibits growth in laboratory studies,
highlighting the importance of sub-lethal subacute exposure [45,46]. While acetaminophen has a
significant potential ecotoxicity, results and concentrations needed to elicit toxicity vary widely
in the literature, and more assessments of non-vertebrates, the foundation of many ecosystems,
are needed [40].
While acetaminophen is unlikely to survive more than 15 days in the environment [45],
pseudo-persistence is a major concern since effluent release areas are constantly bathed with low
levels of medications leading to chronic exposure [47-50]. In some regions, 15 days of survival
is more than enough time for acetaminophen to distribute across a wide area. Even after
degradation, certain photolysis products of acetaminophen may be more toxic than
acetaminophen itself, thus further complicating a comprehensive understanding of
acetaminophen’s environmental impact [51]. Additionally, wastewater effluent also contains
countless other medications; and acetaminophen may amplify the toxicity of other drugs
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[40].While acetaminophen clearly survives into the environment, conventional activated sludge
(and more advanced technologies such as membrane bioreactors) have been shown to remove
>98% of the drug [52-54]. However, given the levels of acetaminophen in the environment is it
likely that much higher removal efficiency is needed to truly prevent its ecological impact.
Sugammadex
Approved by the Federal Drug Administration in 2015, sugammadex has quickly grown
to become one of the most used drugs among anesthesia health care providers. In 2017, 1.38 kg
of sugammadex was administered over 7,073 doses at UVMMC. Sugammadex is renally
eliminated unchanged and it environmental impact is unknown [55]. There is currently a lack of
literature regarding its presence in wastewater streams, its toxicity, and its environmental impact.
However, it is clear that sugammadex may have significant impacts due to its ability to bind to
estrogen and progesterone [56]. Its ability to bind these hormones in humans is so significant that
alternate forms of birth control are needed for 7 days after a single dose of sugammadex. With
its potential as an endocrine disruptor are warranted, further research into the environmental
impacts and especially its potential to be an endocrine disruptor are warranted. Currently, it is
unclear whether it reaches the aquatic environment and whether sugammadex is a source of
environmental externalities from the practice anesthesia.
Lidocaine
Lidocaine was administered nearly 16,000 times for a total of 1.02 kg by UVMMC
anesthesiologists in 2017. Lidocaine is excreted in several different forms. Ten percent is
excreted unchanged by the kidneys, while 90% is metabolized. Lidocaine metabolism produces
mostly monoethylglycinexylidine (MEGX), the major metabolite, and 2,6-xylidine as its minor
product. Both MEGX and 2,6-xylidine undergo renal elimination [57]. MEGX is also further
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metabolized into the potentially carcinogenic 2,6-xylidine [58]. We estimate that 102 grams of
pure lidocaine would have been excreted and upwards of 500 g of MEGX.
Lidocaine and its metabolites have been found in both wastewater and in the environment
as they are only partially removed by wastewater treatment [58]. While the metabolites (MEGX
and 2,6-xylidine) have been found occasionally in wastewater, lidocaine is not fully removed by
treatment and has been found in surface waters and not just waste-streams [58]. While traditional
activated sludge treatment is not fully effective against lidocaine, both PAC/GAC absorption and
ozonation are effective and thus any potential impacts of lidocaine may be mitigated or
prevented [59]. However, lidocaine does not appear to survive long enough in the environment to
reach groundwater stores [58].
Despite this presumed potential for environmental degradation, lidocaine has been found
at least 3 km downstream from a wastewater effluent release location [58]. This indicates the
potential for environmental persistence particularly near any release points. While lidocaine may
be persistent, it is unlikely to bio-accumulate in organisms due to its low lipid solubility. Shortterm tests have not found significant aquatic toxicity from lidocaine; but the long-term studies at
the release points and surrounding environments are lacking [60]. Within the Lake Champlain
waterways, where the discharge ends in a lake, accumulation over time may be significant.
Conclusion
Medications administered by anesthesia health care providers and subsequently excreted
into the water supply system have the potential to affect ecological systems. Currently, it is not
possible to definitively describe the fate of these chemicals in the environment. Some
medications, like propofol, have the potential for significant bioaccumulation and persistence.
Other drugs, such as lidocaine and acetaminophen, have short half-lives in the environment but
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their constant delivery and excretion result in pseudo-persistence. The current literature mostly
assesses acute exposure at doses higher than could be expected in the environment on select
species. While significant toxicities across a variety of species have been found repeatedly,
chronic low dose exposures require further study for all the medications discussed. Finally,
multi-drug impacts are likely to be more impactful than single-drug toxicities [61,62,49,63,50].
While the current literature does not allow for definitive statements regarding the impacts of
anesthetics in the aquatic environment, they have a clear toxic potential and future studies should
more closely examine the relative contribution of anesthesia to pharmaceutical pollution, as well
as points of intervention for minimizing these unintended consequences of healthcare delivery.
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Table 1. Table of the most common drugs administered by the anesthesia service at the
University of Vermont Medical Center in 2017.
Drug

mg

kg

Doses

Cefazolin

23,807,414

23.80741

13,003

Propofol

3,696,145.5

3.696146

48,500

Acetaminophen IV

3,350,373.5

3.350374

4,478

Sugammadex

1,384,146.6

1.384147

7,073

Lidocaine 2% IV

1,019,456

1.019456

15,887

Rocuronium

560,887.73

0.560888

17,323

Ketamine IV

334,560.6

0.334561

18,898

Succinylcholine Chloride

298,443

0.298443

2,584

Methohexital

171,585

0.171585

1,939

Ketorolac

138,031.4

0.138031

5,400

Esmolol

66,228

0.066228

2,515
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